Program
CT-P13 SC Auto-Injector
Also written as “CT-P13 SC Auto-injector”.
Its studies are mostly in Arthritis, Rheumatoid, led by Celltrion.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Celltrion | 20 open or running | phase 3since Dec 10, 2024 | Feb 21, 2018 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 21, 2018First study: phase 1 study in Health, SubjectiveFirst studyNCT03446976 · 218 enrolled · United States
- Dec 10, 2024Phase 3 study in Moderately to Severely Active Rheumatoid ArthritisNCT06738719 · 192 enrolled · Poland
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06738719Moderately to Severely Active Rheumatoid Arthritis · Poland | 3 | Completed | Jun 25, 2025 | 192 |
| NCT03446976Health, Subjective · United States | 1 | Completed | Jul 26, 2018 | 218 |
How it is read
Names in the registry
- “CT-P13 SC Auto-Injector”, 1 entry
- “CT-P13 SC Auto-injector”, 1 entry
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.